IP Library Patent Application 12079167
Patent Application
App. No. 12/079,167

Compositions and methods for treating medical conditions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/079,167
Abstract

The invention features methods, compositions, and kits for the treatment of pain, pruritus, immunoinflammatory disorders, musculoskeletal disorders, and the reduction of serum C reactive protein (CRP) in a patient having a disease or conditions associated with an increased CRP level. The methods, compositions, and kits of the invention provide for a combination therapy including an SSRI and a corticosteroid.

Claims (26)

1 . A method for reducing pain in a patient in need thereof, said method comprising administering to said patient (i) a corticosteroid; and (ii) an SSRI, wherein said corticosteroid and said SSRI are administered in amounts and for a duration that together are sufficient to reduce pain in said patient.

2 . The method of claim 1 , wherein said pain is inflammatory pain, neuropathic pain, or nociceptive pain.

3 . The method of claim 1 , wherein said pain is dysfunctional pain caused by fibromyalgia, tension type headache, irritable bowel disorders, or migraine.

4 . The method of claim 1 , wherein said corticosteroid is algestone, 6-alpha-fluoroprednisolone, 6-alpha-methylprednisolone, 6-alpha-methylprednisolone 21-acetate, 6-alpha-methylprednisolone 21-hemisuccinate sodium salt, 6-alpha, 9-alpha-difluoroprednisolone 21-acetate 17-butyrate, amcinafal, beclomethasone, beclomethasone dipropionate, beclomethasone dipropionate monohydrate, 6-beta-hydroxycortisol, betamethasone, betamethasone-17-valerate, budesonide, clobetasol, clobetasol propionate, clobetasone, clocortolone, clocortolone pivalate, cortisone, cortisone acetate, cortodoxone, deflazacort, 21-deoxycortisol, deprodone, descinolone, desonide, desoximethasone, dexamethasone, dexamethasone-21-acetate, dichlorisone, diflorasone, diflorasone diacetate, diflucortolone, doxibetasol, fludrocortisone, flumethasone, flumethasone pivalate, flumoxonide, flunisolide, fluocinonide, fluocinolone acetonide, 9-fluorocortisone, fluorohydroxyandrostenedione, fluorometholone, fluorometholone acetate, fluoxymesterone, flupredidene, fluprednisolone, flurandrenolide, formocortal, halcinonide, halometasone, halopredone, hyrcanoside, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone probutate, hydrocortisone valerate, 6-hydroxydexamethasone, isoflupredone, isoflupredone acetate, isoprednidene, meclorisone, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, paramethasone, paramethasone acetate, prednisolone, prednisolone acetate, prednisolone metasulphobenzoate, prednisolone sodium phosphate, prednisolone tebutate, prednisolone-21-hemisuccinate free acid, prednisolone-21-acetate, prednisolone-21 (beta-D-glucuronide), prednisone, prednylidene, procinonide, tralonide, triamcinolone, triamcinolone acetonide, triamcinolone acetonide 21-palmitate, triamcinolone diacetate, triamcinolone hexacetonide, and wortmannin.

5 . The method of claim 1 , wherein said SSRI is cericlamine, citalopram, clovoxamine, cyanodothiepin, dapoxetine, duloxetine, escitalopram, femoxetine, 4-(2-fluorophenyl)-6-methyl-2-piperazinothieno[2,3-d]pyrimidine, fluoxetine, fluvoxamine, ifoxetine, indalpine, indeloxazine, litoxetine, milnacipran, paroxetine, sertraline, venlafaxine, viqualine, or zimeldine.

6 . The method of claim 1 , wherein said corticosteroid and said SSRI are formulated in a single composition.

7 . The method of claim 1 , wherein said corticosteroid is in a low dosage.

8 . The method of claim 1 , wherein said composition is formulated for topical, systemic, or oral administration.

9 . The method of claim 1 , wherein said corticosteroid is prednisolone and said SSRI is paroxetine.

10 . The method of claim 1 , wherein 5 to 50 mg of paroxetine are administered to said patient daily.

11 . The method of claim 1 , wherein said prednisolone and paroxetine are formulated in separate dosage forms.

12 . The method of claim 1 , further comprising administering to said patient a third agent selected from the group consisting of antibiotics, disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), anti-convulsants, muscle relaxants, analgesics, cannibinoids, or sedatives.

13 . A method for treating pruritus in a patient in need thereof, said method comprising administering to said patient (i) a corticosteroid; and (ii) an SSRI, wherein said corticosteroid and said SSRI are administered in amounts and for a duration that together are sufficient to treat said patient.

14 . A kit comprising:

(i) a corticosteroid;

(ii) an SSRI; and

(iii) instructions for administering said corticosteroid and said SSRI to a patient for the treatment of pain.

15 . A kit comprising:

(i) a corticosteroid; and

(ii) instructions for administering said corticosteroid with an SSRI to a patient for the treatment of pain.

16 . A kit comprising:

(i) an SSRI; and

(ii) instructions for administering said SSRI with a corticosteroid to a patient for the treatment of pain.

17 . A kit comprising:

(i) a composition comprising a corticosteroid and an SSRI; and

(ii) instructions for administering said composition to a patient for the treatment of pain.

Assignments (2)
CHANGE OF NAME Recorded Oct 15, 2010
From: COMBINATORX, INCORPORATED
To: ZALICUS INC.
Reel/Frame 025150/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2010
From: LESSEM, JAN N.
To: COMBINATORX, INCORPORATED
Reel/Frame 025029/0255 →